Welcome to our dedicated page for Intellia Therapeutics SEC filings (Ticker: NTLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Intellia Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Intellia Therapeutics's regulatory disclosures and financial reporting.
Intellia Therapeutics, Inc. (NTLA) reports that State Street Corporation has filed as an institutional holder of its common stock. State Street reports 9,234,987 shares beneficially owned, representing 6.8% of the outstanding common stock as of the reporting date. It has shared voting power over 8,907,136 shares and shared dispositive power over 9,234,987 shares, with no sole voting or dispositive power. The holding is reported on behalf of State Street and certain investment advisory subsidiaries, including SSGA Funds Management, Inc. and State Street Global Advisors entities.
Intellia Therapeutics reported second quarter 2026 results and major progress in its gene-editing pipeline. In the Phase 3 HAELO trial for hereditary angioedema, one-time treatment lonvo-z met its primary endpoint, reducing attacks by 87% versus placebo over weeks 5–28, with a mean monthly attack rate of 0.26 versus 2.10. Key secondary endpoints all reached statistical significance, including 62% of lonvo-z patients being attack- and therapy-free versus 11% on placebo. Safety findings showed only mild or moderate treatment emergent adverse events and no serious adverse events in the lonvo-z arm. Intellia plans a biologics license application to the FDA with expected acceptance in the second half of 2026 and a potential U.S. launch in the first half of 2027.
For its ATTR amyloidosis program, Intellia advanced Phase 3 MAGNITUDE and MAGNITUDE-2 trials for nex-z and aims to complete MAGNITUDE-2 enrollment in the second half of 2026. A genomic analysis linked higher liver transaminase elevations to one human leukocyte antigen allele, guiding HLA genotyping in ongoing studies. Financially, collaboration revenue was $7,659 thousand in the quarter, research and development expenses were $82,595 thousand, general and administrative expenses were $37,824 thousand, and net loss was $106,634 thousand. Cash, cash equivalents and marketable securities totaled $628,354 thousand at June 30, 2026, which Intellia expects will fund operations at least into 2028.
Intellia Therapeutics EVP and CFO Edward J. Dulac III reported a mandatory sell-to-cover sale of 8,111 shares of common stock on July 22, 2026 to satisfy tax withholding from RSU vesting. The shares were sold at a weighted average price of $11.25, within a range from $11.25 to $11.28, leaving 148,175 shares directly owned.
Intellia Therapeutics, Inc. executive Michael P. Dube, VP and Chief Accounting Officer, reported a sale of 2,641 shares of common stock on July 1, 2026 at a weighted average price of $16.78 per share.
According to the disclosure, this was a mandatory “sell-to-cover” transaction to satisfy tax withholding obligations triggered by the vesting of restricted stock units (RSUs) on the same date, and is explicitly described as not a voluntary trade. After this tax-related sale, Dube held 66,886 shares of Intellia common stock directly.
Intellia Therapeutics EVP and CFO Edward J. Dulac III sold 4,677 shares of Common Stock in an open-market transaction. The sale took place on July 2, 2026 at a price of $18.00 per share and was executed under a pre-established Rule 10b5-1 trading plan adopted on September 8, 2025. After this transaction, Dulac directly holds 156,286 shares of Intellia Therapeutics common stock, indicating he retains a substantial equity stake despite this planned sale.
Intellia Therapeutics reported additional positive Phase 3 data from its global HAELO trial of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema. The study previously met its primary endpoint, showing an 87% reduction in mean monthly attacks in the lonvo-z arm versus placebo during weeks 5 to 28. In that period, 62% of lonvo-z patients were attack free and therapy free compared with 11% on placebo. New key secondary data showed the mean monthly rate of attacks requiring on-demand treatment was 0.19 in the lonvo-z arm versus 1.79 on placebo, an 89% reduction. All treatment-emergent adverse events in the lonvo-z arm were mild or moderate, with no serious adverse events observed. Intellia has initiated a rolling biologics license application for lonvo-z with the FDA and continues to anticipate regulatory approval and a U.S. launch in the first half of 2027.
Intellia Therapeutics director Frank Verwiel received new equity awards. He was granted 9,200 restricted stock units, each representing a contingent right to receive one share of Intellia common stock. Following this grant, he holds 35,148 common shares directly.
He was also awarded a stock option for 13,300 shares of common stock at an exercise price of $12.89 per share. This option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders, and expires on June 8, 2036.
Intellia Therapeutics director Georgia Keresty received equity compensation in the form of restricted stock units and stock options. She acquired 9,200 shares of common stock at no cost through a grant of restricted stock units, bringing her direct holdings to 41,083 shares.
Keresty was also granted stock options covering 13,300 shares of common stock at an exercise price of $12.89 per share. According to the terms, this option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following the grant date.